ArticleTranslational cancer research2021
Progesterone receptor gene serves as a prognostic biomarker associated with immune infiltration in gastric cancer: a bioinformatics analysis.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Stomach at the crossroads: nuclear receptor signaling at the interface between what we are and what we eat.Physiological reviews · 2026Review
- An integrative analysis of UFMylation-related genes reveals a prognostic signature and identifies GDF7 as a novel therapeutic target in gastric cancer.Frontiers in oncology · 2026Article
- Associations between serum sex steroid hormone metabolites and gastric cancer and precancerous lesions in men: A 11.8-year prospective study.Journal of translational internal medicine · 2025Article
- Expression Analysis of miR-519a-3p and miR-379-5p in Colorectal Cancer Patients: A Combined Experimental and Bioinformatic Approach.Diagnostics (Basel, Switzerland) · 2025Article
- Single-cell transcriptome analysis identifies subclusters and signature with N-glycosylation in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Xenoestrogen and Its Interaction with Human Genes and Cellular Proteins: An In-Silico Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.Cancer research · 2023Article
- Functional Proteomic Profiling Analysis in Four Major Types of Gastrointestinal Cancers.Biomolecules · 2023Article
- Value of serum tumor markers in early differential diagnosis of spinal tumors and spinal infections.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is one of the most prevalent cancers globally with a poor prognosis. The progesterone receptor gene (PGR), which encodes the progesterone receptor (PR), can modulate the immune response in many cancers, but its correlation with prognosis and immune infiltration in GC remains unclear. We aimed to investigate the relationship between PGR expression and prognosis in GC patients.
methodsThe expression profile was obtained and the relationship between PGR expression and cancer prognosis was analyzed by Oncomine, Tumor Immune Estimation Resource (TIMER), Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA) database using the minimum P value approach and log-rank method for prognosis analysis. Next, the correlation between the expression level of PGR and immune cell infiltration by the Spearman method using TIMER and GEPIA.
resultsA correlation of elevated PGR expression with poorer prognosis in GC was observed, with overall survival (OS) hazard ratio (HR) was 1.74 [95% confidence interval (CI): 1.4-2.17, P value =6.2e-7] and progression-free survival (PFS) HR was 2.09 (95% CI: 1.58-2.78, P value =1.6e-7). Also, high expression of PGR was related to worse OS and PFS in patients of each N stage in GC, with the highest OS and PFS HR values in stage N1. PGR expression in stomach adenocarcinoma (STAD) was significantly correlated with levels of B cells, CD8+T cells, CD4+T cells, macrophages, neutrophils and dendritic cells. It was also observed that PGR expression was related to a variety of immune cell markers.
conclusionsPGR expression correlated with prognosis and immune cell infiltration in GC, indicating PGR is a potential prognostic biomarker in GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.